EUCTR2017-002860-42-IT进行中（未招募）1 期
A randomized phase II trial of Carboplatin-Paclitaxel-Bevacizumab vs Carboplatin-Paclitaxel-Bevacizumab-Rucaparib vs Carboplatin-Paclitaxel-Rucaparib in patients with advanced (stage III B-C-IV) ovarian, primary peritoneal and Fallopian tube cancer preceded by a phase I dose escalation study on Rucaparib-Bevacizumab combination . - MITO 25
FONDAZIONE POLICLINICO UNIVERSITARIO AGOSTINO GEMELLI IRCCS UNIVERSITA' CATTOLICA DEL SACRO CUORE0 个研究点目标入组 234 人开始时间: 2020年11月4日最近更新:
适应症
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 进行中（未招募）
- 发起方
- 入组人数
- 234
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional clinical trial of medicinal product
入排标准
- 性别
- Female
入选标准
- •1.Women aged = 18 years at the time of study inclusion;
- •2. Patients with newly diagnosed, histologically confirmed, high grade serous, high grade endometrioid, clear cell FIGO stage IIIB-C-IV epithelial ovarian cancer, primary peritoneal cancer and / or Fallopian-tube cancer. Patients with mixed histology (carcinosarcoma) are eligible providing that high grade tumor represent more than 50% of the total histology; other histotypes may be enrolled providing BRCA mutation is present. Stage III patients should have had one attempt at optimal debulking surgery (upfront or interval debulking). Stage IV patients must have had either a biopsy and/or upfront or interval debulking surgery;
- •3. Archival tumor tissue available. At progression fresh biopsy is optional for patients willing to submit ;
- •4. ECOG Performance Status of 0–1;
- •Protocol Version 1.0_18.07.2017 50
- •5. Measurable and not measurable disease;
- •6. Adequate renal and hepatic function, defined as:
- •Total serum bilirubin = 1.5 institutional ULN unless patient has Gilbert’s syndrome in which case total serum bilirubin must be <2 ULN for the institution;
- •-AST and/or ALT = 2.5 x ULN for the institution. (or = 5 x ULN if liver metastases are present);
- •Alkaline phosphatase < 1.5 x ULN for the institution (if > 1.5 x ULN, then alkaline phosphatase liver fraction must be < 1.5 ULN);
- •Serum creatinine = 1.5 x ULN for the institution (or calculated creatinine clearance = 45 mL/min/1.73 m2);
- •7. Adequate bone marrow function, defined as:
- •Total leukocytes = 2.5 x 109/L;
- •ANC = 1.5 x 109/L;
- •Platelet count = 100 x 109/L;
- •8. Able to understand and give written informed consent;
- •9. Females of childbearing potential must have a negative serum pregnancy test within 7 days prior to study enrollment;
- •Are the trial subjects under 18? no
- •Number of subjects for this age range:
- •F.1.2 Adults (18-64 years) yes
- •F.1.2.1 Number of subjects for this age range 174
- •F.1.3 Elderly (>=65 years) yes
- •F.1.3.1 Number of subjects for this age range 60
排除标准
- •1.Women who are pregnant or lactating;
- •2.Presence of brain or other central nervous system metastases, not adequately controlled by treatment;
- •3. Prior Anticancer treatment;
- •4. Inadequate recovery from any prior surgical procedure or having undergone any major surgical procedure within 3 weeks prior to randomization;
- •5. Another primary malignancy except for:
- •a) Curatively treated non-melanoma skin cancer;
- •b) Breast cancer treated curatively =5 years ago, or other solid tumor treated curatively =5 years ago, without evidence of recurrence;
- •c) Synchronous endometrioid endometrial cancer (except for Stage 1A G1/G2);
- •6. Known active HIV, hepatitis B or C infection;
- •7. Concurrent treatment with immunosuppressive or investigational agents;
- •8. History or evidence of thrombotic or hemorrhagic disorders; including cerebrovascular accident (CVA) / stroke or transient ischemic attack (TIA) or subarachnoid haemorrhage within _6 months prior to the first study treatment);
- •9. Clinically significant (i.e. active) cardiovascular disease, including:
- •- Myocardial infarction or unstable angina within _6 months prior to the first study treatment;
- •- New York Heart Association (NYHA) grade II or greater congestive heart failure (CHF);
- •- Serious cardiac arrhythmia requiring medication (with the exception of atrial fibrillation or paroxysmal supraventricular tachycardia);
- •- Peripheral vascular disease > grade 3 (i.e.symptomatic and interfering with activities of daily living requiring repair or revision);
- •10. Serious active infection requiring i.v. antibiotics at enrolment;
- •11. Known hypersensitivity to any of the study drugs or excipients (including cremophor and hamster Ovary cell products);
- •12. Evidence of any other medical conditions (such as psychiatric illness, peptic ulcer, etc.), physical examination or laboratory findings that may interfere with the planned treatment, affect patient compliance or place the patient at high risk from treatment related complications;
- •13. Prior gastrectomy or upper bowel removal, or any other gastrointestinal disorder or defect that would interfere with absorption of study drug;
- •14. Received administration of strong CYP1A2 or CYP3A4 inhibitors = 7 days prior to first dose of Rucaparib or have on going requirements for these medications.
研究者
相似试验
进行中（未招募）
不适用
Carboplatin-Paclitaxel compared to Carboplatin-Paclitaxel-Bevacizumab in advanced (stage III-IV) or recurrent endometrial cancer.endometrial cancerMedDRA version: 14.1Level: LLTClassification code 10014770Term: Endometrioid adenocarcinomaSystem Organ Class: 10029104 - Neoplasms benign, malignant and unspecified (incl cysts and polyps)EUCTR2011-003301-16-ITPOLICLINICO UNIVERSITARIO AGOSTINO GEMELLI108
已完成
2 期
A clinical trial to study the effects of carboplatin / Paclitaxel and a new drug, CS- 7017, in patients with Non-Small Cell Lung CancerCTRI/2010/091/000491Daiichi Sankyo Pharma Development399 Thornall StreetEdison, NJUSA115
进行中（未招募）
不适用
A randomised phase II pilot trial of carboplatin compared to docetaxel for patients with metastatic genetic breast cancer.Ensayo piloto randomizado en fase II que compara carboplatino y docetaxel en pacientes con cáncer de mama genético metastásico. - BRCA TrialEUCTR2004-001496-20-ESniversity College London
已完成
2 期
A Randomized Phase II study of Carboplatin and Paclitaxel or Gemcitabine and Vinorelbine in ECOG PS2 patients with advanced non-small cell lung cancerJPRN-C000000097West Japan Oncology Group90
进行中（未招募）
1 期
A randomized phase II trial of standard carboplatin-based chemotherapy with or without panitumumab in platinum-sensitive recurrent ovarian cancerPlatinum-sensitive recurrent ovarian cancerMedDRA version: 19.1Level: LLTClassification code 10033131Term: Ovarian carcinomaSystem Organ Class: 100000004864EUCTR2010-018849-59-DEGMIHO Gesellschaft für Medizinische Innovation - Hämatologie und Onkologie mbH